Filling the need for trusted information on national health issues…

Trending on kff Ebola Marketplaces Enrollment

Tuberculosis

  • your selections
Clear Search

Filter Results

date

Tags

  • results
Novel Financing Mechanisms Needed To Improve Access To Multidrug-Resistant TB Treatment

PLOS Medicine: Global Financing and Long-Term Technical Assistance for Multidrug-Resistant Tuberculosis: Scaling Up Access to Treatment Thomas Hwang of Harvard University and the Blackstone Group, and Salmaan Keshavjee of Harvard University and Partners in Health, explore issues surrounding scaling up access to treatment for multidrug-resistant tuberculosis, including novel financing structures…

The Atlantic Examines Challenges Surrounding TB Vaccine Development

The Atlantic: Toward an Effective Tuberculosis Vaccine “…While we have vaccines to thank for the decline of global diseases like measles and smallpox, vaccination’s role in the worldwide battle against TB has been comparatively minimal. … So, what is it about a TB vaccine that’s had science stymied for over…

Tools Available To Prevent Pediatric Tuberculosis

Huffington Post: The Preventable Disease We Should All Be Fighting Against Paul Stoffels, chief scientific officer at Johnson & Johnson “Childhood tuberculosis (TB) is a serious problem that has received inadequate attention, in large part because we simply didn’t know the magnitude of the problem. … This is not acceptable,…

Liberia Struggles To Contain Ebola, Treat Patients With Ebola, Other Diseases

News outlets report on the situation in Liberia, where Ebola continues to spread and its health system struggles to treat Ebola patients as well as those with other diseases. CNN: New Ebola hospital in Liberia overwhelmed by patients “On the day the new Ebola clinic in Liberia opened, ambulances waited…

TB Studies Highlight Treatment Needs, Opportunities

Center for Global Health Policy’s “Science Speaks”: TB trials highlight needs, opportunities Antigone Barton, writer and editor of “Science Speaks” and senior communications officer at the Center for Global Health Policy, discusses results from two tuberculosis studies that “could change approaches to treatment delivery and development, but only if funding…

Political Will Needed To Head Off Looming TB-Diabetes Co-Epidemic

The Hill: We must prevent the looming epidemic of TB-diabetes Anthony Harries, senior adviser and director of the Department of Research at the International Union Against Tuberculosis and Lung Disease “Hall of Fame hockey player Wayne Gretzky had a famously successful strategy: don’t skate to the puck, skate to where…

South Africa’s Mortality Rate Dropped In 2012; TB Remained Leading Cause Of Death

Bloomberg News: South African Death Rate Fell in 2012 as TB Stays Top Killer “South Africa’s mortality rate dropped six percent in 2012 as antiretroviral therapy programs helped cut deaths of HIV-infected patients. Tuberculosis remained the leading killer. The number of deaths in the continent’s second-largest economy dropped to 480,476…

Policy Brief Series Highlights Need For Europe To Invest More In Global Health

DSW Blog: Why invest in R&D for HIV, TB and malaria? Because it’s good for global health, and good for Europe Eoghan Walsh, communications officer at Deutsche Stiftung Weltbevoelkerung (DSW), introduces “a series of policy briefs on the issue of global health research and development, outlining why we need to…

New Issue Of ‘Global Fund News Flash’ Available Online

Global Fund to Fight AIDS, Tuberculosis and Malaria: Global Fund News Flash Issue 48 of the Global Fund News Flash discusses five general and six technical recommendations “identifying areas where concept notes could be strengthened” under the new funding model (9/1).

The Guardian Speaks With Experts About Experimental New TB Drug PaMZ

The Guardian: What does new drug PaMZ mean for TB and HIV treatment? “Earlier this year, the TB Alliance announced that it was ready to start clinical trials for PaMZ, its new tuberculosis (TB) drug. PaMZ is a combination of three drugs, two of which have not been licensed for…